πŸ‡ΊπŸ‡Έ FDA
Patent

US 11826327

Treatment for interstitial lung disease

granted A61KA61K31/192A61K31/5575

Quick answer

US patent 11826327 (Treatment for interstitial lung disease) held by United Therapeutics Corporation expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
United Therapeutics Corporation
Grant date
Tue Nov 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/192, A61K31/5575, A61K9/0075, A61K9/0078